Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MethylGene has reported encouraging preclinical data for MGCD265, an oral, multi-targeted kinase inhibitor for cancer that targets the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases.
Subscribe to our email newsletter
Results from in vivo human tumor models in mice demonstrated significant inhibition of tumor growth in a broad range of cancer types. In c-Met driven gastric cancer and glioblastoma tumor models, MGCD265 decreased tumor volume by more than 95% compared to untreated tumors.
Furthermore, MGCD265 showed anti-tumor activity in breast, colorectal and non-small cell lung cancer tumor models that were not c-Met driven, with an average reduction in tumor volume of 76%. MGCD265 potently inhibited c-Met and VEGFR2 cellular phenotypes, including cell motility and angiogenesis. Biomarker analysis also revealed potent inhibition of in vivo c-Met signal transduction activity and inhibition of downstream Erk and Akt signaling pathways.
MethylGene expects to commence a dose-escalating, Phase I clinical trial (trial 102) for this compound in solid tumor cancers in April 2008, followed by a second Phase I trial in the second quarter of 2008.